Literature DB >> 31646079

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade.

Oliver Kepp1,2,3,4,5, Laurence Zitvogel6,7,8,9,10, Guido Kroemer11,12,13.   

Abstract

In preclinical in vivo models of cancer, the induction of immunogenic cell death (ICD) sensitizes to subsequent immunotherapy. Several clinical trials now confirm that pretreatment with ICD-inducing anthracyclines sensitizes to immune checkpoint blockade targeting PD-1 and PD-L1 interaction. These findings support the translational utility of the concept of ICD.
© 2019 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Anthracyclins; PD-1; PD-L1; immunogenic cell death

Year:  2019        PMID： 31646079      PMCID： PMC6791413          DOI： 10.1080/2162402X.2019.1637188

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

2.  Tumor lysis with LTX-401 creates anticancer immunity.

Authors:  Wei Xie; Laura Mondragón; Brynjar Mauseth; Yan Wang; Jonathan Pol; Sarah Lévesque; Heng Zhou; Takahiro Yamazaki; Johannes J Eksteen; Laurence Zitvogel; Baldur Sveinbjørnsson; Øystein Rekdal; Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-13       Impact factor: 8.110

3.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

4.  Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

Authors:  Johan Aurelius; Lars Möllgård; Roberta Kiffin; Frida Ewald Sander; Staffan Nilsson; Fredrik Bergh Thorén; Kristoffer Hellstrand; Anna Martner
Journal:  Leuk Lymphoma       Date:  2019-04-17

5.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 6.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

7.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Authors:  Leonie Voorwerk; Maarten Slagter; Hugo M Horlings; Karolina Sikorska; Koen K van de Vijver; Michiel de Maaker; Iris Nederlof; Roelof J C Kluin; Sarah Warren; SuFey Ong; Terry G Wiersma; Nicola S Russell; Ferry Lalezari; Philip C Schouten; Noor A M Bakker; Steven L C Ketelaars; Dennis Peters; Charlotte A H Lange; Erik van Werkhoven; Harm van Tinteren; Ingrid A M Mandjes; Inge Kemper; Suzanne Onderwater; Myriam Chalabi; Sofie Wilgenhof; John B A G Haanen; Roberto Salgado; Karin E de Visser; Gabe S Sonke; Lodewyk F A Wessels; Sabine C Linn; Ton N Schumacher; Christian U Blank; Marleen Kok
Journal:  Nat Med       Date:  2019-05-13       Impact factor: 53.440

8.  Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Authors:  Peng Liu; Liwei Zhao; Jonathan Pol; Sarah Levesque; Adriana Petrazzuolo; Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Takahiro Yamazaki; Kristina Iribarren; Laura Senovilla; Lucillia Bezu; Erika Vacchelli; Valentina Sica; Andréa Melis; Tiffany Martin; Lin Xia; Heng Yang; Qingqing Li; Jinfeng Chen; Sylvère Durand; Fanny Aprahamian; Deborah Lefevre; Sophie Broutin; Angelo Paci; Amaury Bongers; Veronique Minard-Colin; Eric Tartour; Laurence Zitvogel; Lionel Apetoh; Yuting Ma; Mikael J Pittet; Oliver Kepp; Guido Kroemer
Journal:  Nat Commun       Date:  2019-04-02       Impact factor: 14.919

9.  A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

Authors:  Lucia D'Amico; Ulrike Menzel; Michael Prummer; Philipp Müller; Mélanie Buchi; Abhishek Kashyap; Ulrike Haessler; Alexander Yermanos; Rémy Gébleux; Manfred Briendl; Tamara Hell; Fabian I Wolter; Roger R Beerli; Iva Truxova; Špíšek Radek; Tatjana Vlajnic; Ulf Grawunder; Sai Reddy; Alfred Zippelius
Journal:  J Immunother Cancer       Date:  2019-01-21       Impact factor: 13.751
  9 in total
  22 in total

1.  Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Authors:  Kathleen N Moore; Michael Bookman; Jalid Sehouli; Austin Miller; Charles Anderson; Giovanni Scambia; Tashanna Myers; Cagatay Taskiran; Katina Robison; Johanna Mäenpää; Lyndsay Willmott; Nicoletta Colombo; Jessica Thomes-Pepin; Michalis Liontos; Michael A Gold; Yolanda Garcia; Sudarshan K Sharma; Christopher J Darus; Carol Aghajanian; Aikou Okamoto; Xiaohua Wu; Rustem Safin; Fan Wu; Luciana Molinero; Vidya Maiya; Victor K Khor; Yvonne G Lin; Sandro Pignata
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 50.717

2.  Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Authors:  Annamaria Gulla; Eugenio Morelli; Mehmet K Samur; Cirino Botta; Teru Hideshima; Giada Bianchi; Mariateresa Fulciniti; Stefano Malvestiti; Rao H Prabhala; Srikanth Talluri; Kenneth Wen; Yu-Tzu Tai; Paul G Richardson; Dharminder Chauhan; Tomasz Sewastianik; Ruben D Carrasco; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood Cancer Discov       Date:  2021-04-23

Review 3.  Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.

Authors:  Zahra Asadzadeh; Elham Safarzadeh; Sahar Safaei; Ali Baradaran; Ali Mohammadi; Khalil Hajiasgharzadeh; Afshin Derakhshani; Antonella Argentiero; Nicola Silvestris; Behzad Baradaran
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

Review 4.  Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review.

Authors:  Rachid Bouzid; Maikel Peppelenbosch; Sonja I Buschow
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

5.  Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In Vitro.

Authors:  Zhiying Huang; Haifeng Hu
Journal:  Molecules       Date:  2021-01-19       Impact factor: 4.411

6.  Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy.

Authors:  Yan Wang; Wei Xie; Juliette Humeau; Guo Chen; Peng Liu; Jonathan Pol; Zhen Zhang; Oliver Kepp; Guido Kroemer
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

7.  A novel platinum-based chemotherapeutic inducing immunogenic cell death.

Authors:  Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2020-02-15       Impact factor: 8.110

Review 8.  Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.

Authors:  Zihui Li; Jie Deng; Jianhai Sun; Yanling Ma
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

9.  Novel galenic formulations for delivering immunochemotherapies: kill intelligently, remove the checkpoint and let the T cells in!

Authors:  Oliver Kepp; Guido Kroemer
Journal:  Oncoimmunology       Date:  2020-11-16       Impact factor: 8.110

Review 10.  Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy.

Authors:  Erwan Eriau; Juliette Paillet; Guido Kroemer; Jonathan G Pol
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.